Could probiotics be a breath of fresh air for COPD?
NCT ID NCT07339280
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether taking probiotic capsules daily for 16 weeks can reduce shortness of breath and improve lung function in people with COPD. Sixty adults with stable COPD will receive either the probiotic or a placebo. Researchers will measure changes in breathing, symptoms, and inflammation to see if probiotics offer any benefit.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- probiotic supplement (Lactobacillus plantarum and Saccharomyces boulardii)
- What this could lead to
- If it works, this could point toward a simple, safe way to help people with COPD breathe easier and feel better day-to-day.
- What could go wrong
- This is a small, early-stage trial with only 60 people. Probiotics may not improve COPD symptoms, and results might not apply to everyone with the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2026
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients with a previously established diagnosis of COPD, regardless of the degree of airflow obstruction on pulmonary function testing. 2. Age over 18 years, regardless of sex. 3. Stable disease without exacerbations during the past two months (8 weeks). 4. Stable disease without changes to maintenance therapy during the past two months (8 weeks). 5. Patients with an mMRC score of 1 or higher. 6. Signed informed consent. Exclusion Criteria: 1. patients diagnosed with serious comorbidities such as severe cardiovascular diseases (severe heart failure, acute coronary syndrome, or percutaneous coronary intervention within 6 months, uncontrolled tachy/bradyarrhythmias), patients with severe renal failure and a placed central venous catheter, patients with severe liver damage (Child-Pugh class C), patients with infectious hepatitis or HIV, active bloody diarrhea; 2. patients undergoing active oncological and hematological treatment; 3. patients who have had a stroke within the past 3 months; 4. transplanted patients, including allograft recipients; 5. patients on long-term systemic corticosteroid and immunosuppressive therapy (oral or intravenous form) as well as antifungal therapy, 6. patients who have had a COPD exacerbation within the past two months and are not in a stable condition, 7. patients diagnosed with asthma, 8. patients with a history of lung surgery or serious respiratory diseases other than COPD (active tuberculosis, sarcoidosis, pulmonary fibrosis, severe bronchiectasis, pulmonary aspergillosis, etc.), 9. patients who have recently participated in other clinical trials or have received experimental therapy, 10. patients with a history of severe allergic reactions or hypersensitivity to the components of the probiotic preparation, 11. patients with active alcoholism or drug addiction, 12. patients with severe psychiatric diagnoses or those with significant physical or cognitive limitations that would interfere with following the study protocol, 13. patients who have recently undergone surgery, 14. pregnant or breastfeeding women, 15. patients who have taken any probiotic preparations within one month before the start of the study, 16. patients whose COPD treatment is changed during the course of the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
5 sites. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
General Hospital Karlovac
Karlovac, Croatia
-
General Hospital Sibenik
Šibenik, 2200, Croatia
-
General Hospital Vinkovci
Vinkovci, Croatia
-
University Hospital Centre Sestre milosrdnice
Zagreb, Croatia
-
University Hospital Split
Split, 2100, Croatia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Patient's own airway stem cells repair damaged lungs in COPD?
- Can Device-Preserved donor lungs boost transplant success?
- Dead probiotic bacteria put to the test in Kids' saliva
- Tiny One-Way valves for emphysema under close watch in japan
- Six biologics put to the test in Real-World asthma and COPD care
- Is RSV a hidden driver of severe COPD attacks?